Atara, Ocular Therapeutix jump onto the biotech IPO wave; Novo posts more positive liraglutide data;

@FierceBiotech: Roche partners with Versant on a new build-to-sell biotech on MS. More | Follow @FierceBiotech

@JohnCFierce: FDA review red-flags AstraZeneca's case for ovarian cancer drug olaparib. Story | Follow @JohnCFierce

@DamianFierce: Amazing first line of a BIO 2014 email: "As you have probably heard Steve Burrill is unable to attend BIO this year." Yeah, I heard. | Follow @DamianFierce

@EmilyMFierce: Stem cell treatment for horses to be tried in humans. Story via BBC News | Follow @EmilyMFierce

Brisbane, CA-based Atara Biotherapeutics has filed plans to raise about $50 million in an IPO. The biotech is working on muscle-wasting and ovarian cancer drugs, reports the Silicon Valley Business Journal. Atara has attracted support from Kleiner Perkins, Domain, DAG, Celgene and Amgen, which provided some of the programs it is working on. Story

Bedford, MA-based Ocular Therapeutix filed an S-1 outlining plans for an $86 million IPO. At the beginning of this year the biotech won an FDA approval for a gel designed to plug incisions made during cataract surgery. S-1

Novo Nordisk posted more positive data on its diabetes drug liraglutide, this time from a Phase IIIa study. Release

Medical Device News

@FierceMedDev: Apple, Google stalk wearable med tech with glucose monitoring up first. Feature | Follow @FierceMedDev

@StacyALawrence: AbbVie says Shire has spurned three buyout offers, won't rule out new bid. Story from Friday | Follow @StacyALawrence

@MichaelGFierce: UPenn team combats Parkinson's with immunotherapy that targets neuron killers. Story from FierceBiotechResearch | Follow @MichaelGFierce

@EmilyWFierce: Medtronic reveals cyberattack and lost patient data in latest regulatory filing. More | Follow @EmilyWFierce

> In test of FDA guidelines, medical mobile app Abriiz escapes scrutiny. News

> FDA to stop regulating some medical device software. More

Pharma News

@FiercePharma: Top-read on FP this weekend: Why does #Sovaldi cost $84,000? Gilead being pressed hard for an answer. Story | Follow @FiercePharma

@TracyStaton: ICYMI, the latest in the #Sovaldi pricing squabble: Congress wants to get involved. More | Follow @TracyStaton

@EricPFierce: How much are the big dogs of Big Pharma paid? A lot. See the top 15 highest paid CEOs here. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Italian officials probe Novartis for possible flu vaccine pricing fraud. News | Follow @CarlyHFierce

> Chinese drugmaker plots $761M stock offering to fund deals, R&D. More

> Shire touts $10B sales target to fend off AbbVie as other suitors circle. Story

> The FTC launches new pay-for-delay probes, hoping to win some. News

> Cubist's Trius buyout pays off with FDA nod on high-powered antibiotic Sivextro. Article

CRO News

> Teva settles with Catalent, Perrigo in inhaler patent suit. Item

> Parexel rolls out new eClinical tech to speed up study start-up. Story

> Simbec buys its way into late-stage R&D with Orion deal. Article

> Japanese CRO taps BBK for a U.S. joint venture. News

> Quintiles partners up to flex its commercial muscles. More

> BioClinica dives into adaptive trials with latest buy. Report

Biotech IT News

> Survey: Biopharma still reliant on paper, email for sharing TMFs. Item

> USC in talks to buy or affiliate with Scripps. Story

> AstraZeneca opens up compound library to select academics. More

> FDA's long-awaited Twitter guidance gives biopharma certainty and constraints. Article

> Big Pharma consortium adds redaction of trial information to list of initiatives. News

> Tech vendors flock to DIA to show off new software. Report

Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.